IngredientsFu Ling is derived from Poria cocos — the dried sclerotia of Wolfiporia cocos (F.A. Wolf) Ryvarden & Gilb., which is also referred to as "Fuling" in China. The genus name Poria places it in the family Polyporaceae. In modern mycological taxonomy, the accepted binomial is Wolfiporia cocos (also encountered in older literature as Wolfiporia extensa). Its name was changed in the 1980s to Wolfiporia cocos, then Wolfiporia extensa. In Chinese the material is rendered 茯苓, romanised as Fú Líng in Pinyin. It is also known in English-language sources as Poria, hoelen, tuckahoe, Indian bread, and China root.
Poria cocos (Polyporaceae) is a saprophytic fungus that grows in diverse species of Pinus. It is derived from the dried sclerotium of the basidiomycete fungus Poria cocos (Schw.) Wolf., a species that parasitizes the roots of pine trees such as red pine or masson pine. Poria cocos is an annual fungus that relies on its mycelium to decompose, absorb, and transform nutrients from the host or culture material for growth and development. Throughout different stages of development, Poria cocos often exhibits three distinct morphological structures: mycelium, sclerotia, and fruiting body.
Poria is a saprophytic fungus that grows on pine tree roots; its large, potato-shaped formation known as a sclerotium can grow up to 30 cm in length and 1 kg in mass. The texture is soft and elastic, and the flavor is sweet and bland. The fungus is harvested and then dried in the shade. The sclerotium is the commercially and medicinally relevant part; it represents a compacted mass of mycelial tissue that serves as a nutrient-storage organ.
Poria cocos is primarily found in Asia, America, Oceania, Africa, and other regions. China serves as the main cultivation region, accounting for approximately 70% of the global cultivation area. Its distribution in China is mainly in the regions south of the Yangtze River, with provinces such as Yunnan, Hunan, Guangxi, Hubei, Guizhou, Fujian, and Anhui having shown high yields through artificial cultivation. Poria cocos has an active import and export trade, with a long history of exports that can be traced back to the 8th century.
TCM practice distinguishes several preparations depending on which anatomical layer of the sclerotium is used:
In the market, a comprehensive application system has been formed, including pieces, proprietary Chinese medicines, ordinary food, functional food, cosmetics, and veterinary drugs. Raw slices and cubes, powders, standardised extracts in capsules or tablets, granules for decoction, and traditional decoction pieces are the most widely distributed forms.
Poria cocos (Fu Ling) is a traditional medicinal fungus with more than two millennia of documented use, which occupies a central role in East Asian medical practice. The application of Poria cocos has a history of over 2,500 years. Poria cocos, the dried sclerotium of the fungus (family Polyporaceae), is one of the most important medicinal and edible homologous materials in traditional Chinese medicine. First documented as a "superior-grade" herb in the Divine Farmer's Classic of Materia Medica (Shennong Bencao Jing), it has been extensively referenced in subsequent classical texts. The Shennong Bencao Jing is the earliest extant materia medica text, compiled in the Eastern Han Dynasty (25–220 AD). It records 365 medicinals and summarises medicinal experiences up to the Han Dynasty. Medicinals are classified into three categories — high-grade, medium-grade, and low-grade — based on their medicinal effects and toxicity. Fu Ling was listed in the highest, "superior-grade" category.
Poria cocos is renowned for its unique properties, meridian tropisms, and therapeutic applications, which have been systematically documented in classical texts such as the Shennong's Classic of Materia Medica (Shennong Bencao Jing) and the Compendium of Materia Medica (Bencao Gangmu).
Poria cocos is characterised as sweet, bland, and neutral in nature. The "sweet" property aligns with its tonifying and harmonising effects, particularly in fortifying the Spleen and stabilising bodily fluids. The "bland" and "neutral" properties ensure its gentle action. It primarily enters the Spleen, Heart, Lung, and Kidney meridians. Its affinity for the Spleen underscores its role in resolving dampness and improving digestion, while its connection to the Heart and Kidney meridians highlights its calming and diuretic effects.
According to the Chinese Pharmacopoeia, Poria cocos is mainly used for edema, oliguria, phlegm, dizziness, palpitations, Spleen deficiency, reduced appetite, loose stools, diarrhea, restlessness, and insomnia. Classical therapeutic indications include promoting diuresis, strengthening the Spleen, and calming the mind.
Fu Ling's versatility made it one of the most frequently combined herbs in the TCM tradition. In terms of medicinal use, Poria cocos has the reputation of "Nine out of ten prescriptions contain Poria cocos" since ancient times.
The sclerotium, called fu-ling or hoelen, is used in traditional Chinese and Japanese medicine for its diuretic, sedative, and tonic effects. In Kampo (traditional Japanese medicine), many compound formulas incorporating Poria cocos remain in use today, several of which are covered by the Japanese National Health Insurance system.
Poria cocos has received official recognition as one of the initial groups of Chinese medicines authorised for both medicinal and culinary purposes in China. It is one of the first batches of herbs designated as both medicine and food in China. Historically, the sclerotium was ground into a powder and incorporated into pastries, congee, soups, and teas. Poria was once used to make a variety of delicacies and snacks for members of the royal family. The fungus has a long history of use in Southern China, where it was ground into a powder and used daily.
Polysaccharides (comprising 70–90% of the dry weight of Poria cocos) and triterpenoids constitute the primary chemical constituents of Poria cocos, serving as the key bioactive compounds responsible for its pharmacological actions. Phytochemical analysis has determined that polysaccharides and triterpenes are the main bioactive components, and 120 triterpenoid compounds have been reported. Other minor ingredients include histidine, amino acids, choline, steroids, and potassium salts.
Based on their structural characteristics, Poria cocos polysaccharides can be classified into two main categories. The first is β-pachyman, which primarily consists of β-(1→3)-D-glucan with limited (1→6) and (1→2) branching. β-Glucan is the major Poria cocos polysaccharide with a β-(1→3)-linked glucose backbone and β-(1→6)-linked glucose side chains. P. cocos polysaccharides consist of ribose, arabinose, xylose, mannose, glucose, and galactose. Following oral administration, polysaccharides are minimally digested in the small intestine but can act as potential prebiotics for gut microorganisms, thereby shaping the composition and metabolic function of the gut microbiota.
The sterols are mostly tetracyclic triterpenoids classified as lanostane and secolanostane, including pachymic acid, tumulosic acid, polyporenic acid C, ebricoic acid, and poricoic acid.
Pachymic acid (PA) is the main lanostane-type triterpenoid in Poria cocos. Evidence suggests that PA has various biological properties such as cytotoxic, anti-inflammatory, antihyperglycaemic, antiviral, antibacterial, sedative-hypnotic, and anti-ischaemia/reperfusion activities. PA is a white powder and is highly insoluble in water. Therefore, the poor solubility of PA results in its low bioavailability in vivo, which may limit its further clinical applications. Cai et al. demonstrated that glycyrrhizin (a triterpenoid glycoside) increases the solubility of PA in an aqueous solution, thereby improving its bioavailability.
Six major lanostane triterpenoid compounds isolated from Poria cocos are: pachymic acid, dehydropachymic acid, tumulosic acid, dehydrotumulosic acid, polyporenic acid C, and 3-epi-dehydrotumulosic acid. Additionally, lanostane-type triterpenes including dehydrotrametenolic acid, dehydropachymic acid, and 3-O-acetyl-16α-hydroxy-dehydrotrametenolic acid, and 3,4-secolanostane-type triterpenes including poricoic acids A, B, and D have been identified from Poria cocos.
The triterpenes (lanostane and 3,4-secolanostane skeletons) and polysaccharides (β-pachyman) are the main components, and they have exhibited various biological activities such as anti-tumour, antibacterial, and antioxidant properties. Beyond these two primary classes, the sclerotium also contains ergosterol and other sterols, fatty acids, proteins, and volatile oils including linalool and methyl phenylacetate. Among the 62 compounds identified by HS-GC/MS analysis from the essential oil, the two main fragrances in common were linalool and methyl phenylacetate.
Polysaccharides from Poria cocos enhanced the secretion of immune stimulators and suppressed the secretion of immune suppressors, thus potentiating the immune response. In several studies reviewed, the inhibitory effects of triterpenes on phospholipase A2 (PLA2) have been clearly demonstrated. In addition, the inhibitory effects of Poria cocos on the secretion of different cytokines from human peripheral blood monocytes have also been described.
P. cocos mediates its pharmacological anti-inflammatory properties via two triterpenoids, namely pachymic acid and dehydrotumulosic acid. At the cellular level, six triterpenoids were isolated from Poria cocos and their effects on the levels of NO and PGE2 (prostaglandin E2) and on the expression of inducible iNOS and COX-2 (cyclooxygenase-2) in LPS-induced Raw 264.7 cells were observed. The results showed that several compounds might inhibit the production of NO and expression of iNOS in LPS-induced Raw 264.7 cells. Compound 1 decreased PGE2 level by down-regulating the expression of COX-2. Compounds 22 and 29 showed obvious inhibitory effects (IC50: 18.27 μM and 16.87 μM, respectively) on LPS-induced NO production by reducing the expression of inducible NO synthase enzymes in RAW 264.7 cells, which might be regulated via blocking the signalling pathway of activator protein-1.
The antitumour properties of Poria cocos involve multiple mechanisms, such as inhibition of cellular proliferation and metastasis, induction of apoptosis and cell cycle arrest, and modulation of immune, inflammatory, and oxidative signalling pathways. For polysaccharides specifically, their anticancer activity is associated with stimulation of the immune response. For triterpenes, the anti-proliferative effects of the triterpene extract on BxPc-3 (pancreatic cancer) cells are mediated by cell cycle arrest at the G0/G1 phase. DNA microarray analysis demonstrated that the extract significantly downregulates the expression of KRAS and matrix metalloproteinase-7 (MMP-7).
The Poria cocos extract (PCET) can improve sleep quality and structure by promoting inhibitory neurotransmission via the γ-aminobutyric acid (GABA) type A (GABAA) receptors, based on mechanisms revealed in experiments with superior cervical ganglion neurons. Poria contains triterpenoids and polysaccharides, which are reported to regulate the cytoplasmic free calcium associated with the N-methyl-D-aspartate receptor and affect the cell function of neonatal rat nerve cells and hippocampal neurons. Pachymic acid also exhibits neuroprotective properties by regulating genes within the NF-κB and IL-17 pathways, reducing Fe²⁺-induced ROS, and stabilising mitochondrial membrane potential, thereby preventing neuronal apoptosis.
The anti-diabetic mechanism of P. cocos and its triterpenes are likely due to their abilities to sensitise insulin-mediated glucose uptake. These findings provide insights into the mechanism of action of P. cocos and its active triterpenes against diabetes.
Polysaccharides may confer therapeutic benefits primarily through modulation of gut microbiota and their metabolites, whereas triterpenoids may act through direct target interactions, with the two components potentially working in concert to produce enhanced efficacy. P. cocos polysaccharides were readily utilised by the gut microbiota, as evidenced by a significant decrease in pH and an increase in short-chain fatty acid (SCFA) concentrations. Notably, the relative abundance of beneficial bacteria (e.g., Lactobacillus and Bifidobacterium) increased, whereas that of potentially pathogenic taxa (e.g., Escherichia-Shigella and Bilophila) decreased.
Poricoic acid A (PAA) at 20 mg/kg has protective effects on kidney fibrosis induced by a high-salt diet in mice. It could reduce kidney index and urinary protein levels, improve renal tubular dilation and kidney tissue fibrosis, and activate the AMP-activated protein kinase (AMPK) signalling pathway in the kidneys. The core mechanism involves regulating the balance of the gut microbiota, increasing the abundance of beneficial bacteria such as Lactobacilli and Akkermansia, reducing the proportion of endotoxin-producing bacteria like Desulfovibrio, and promoting the production of short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate.
Evidence quality: Mostly preclinical (in vitro and animal); limited direct human trials on Fu Ling alone.
Triterpenoids are known to have a pivotal influence on certain diseases such as rheumatoid arthritis, psoriasis, autoimmune uveitis, septic shock, and possibly bronchial asthma, while polysaccharides can potentiate the immune response. Some Poria polysaccharide formulations are used clinically as adjunctive antitumour or antiviral agents in parts of Asia. The specific immunological targets that have been characterised in cell studies include TLR4/MD2/NF-κB pathway activation and stimulation of macrophage phagocytosis. However, well-controlled human trials using Fu Ling or its isolated polysaccharides as the sole intervention in immunological outcomes remain sparse.
Evidence quality: Primarily in vitro and animal studies; some multi-ingredient RCT data for adjuvant use, with significant methodological limitations.
Reviews elucidate the antitumour properties of Poria cocos on various cancers, including lung, colorectal, breast, and gastric cancers. These properties involve inhibition of cellular proliferation and metastasis, induction of apoptosis and cell cycle arrest, and modulation of immune, inflammatory, and oxidative signalling pathways.
In pancreatic cancer cell lines specifically, a characterised mixture of triterpenes extracted from P. cocos (PTE) and three purified triterpenes — pachymic acid (PA), dehydropachymic acid (DPA), and polyporenic acid C (PPAC) — suppress the proliferation of human pancreatic cancer cell lines Panc-1, MiaPaca-2, AsPc-1, and BxPc-3. Moreover, the most effective compound, PA, only slightly affects the proliferation of HPDE-6 normal pancreatic duct epithelial cells. These are preclinical, in vitro findings only.
For gastric cancer, a preclinical study found that PA can significantly alter the expression of EMT-related proteins E-cadherin, N-cadherin, and Vimentin, and decreased the expressions of metastasis-related proteins MMP-2, MMP-9, and TIMP1 in gastric cancer cells. Triterpenoids from P. cocos have significant biological activity against gastric cancer, and the mechanism may involve the process of epithelial–mesenchymal transformation.
In the area of ovarian cancer adjuvancy, a systematic literature search of eight databases was performed to evaluate the efficacy and safety of Poria cocos-based formulas in combination with paclitaxel–carboplatin in treating ovarian cancer. Thirteen randomised controlled trials including 922 patients with ovarian cancer were enrolled. The results indicated that Poria cocos-based compounds combined with paclitaxel–carboplatin significantly improved patients' tumour response rate, TCM syndrome score, Karnofsky Performance Scale, physical and social function, and reduced side effects of chemotherapy compared to paclitaxel–carboplatin alone. Critically, the included trials were small RCTs in China, which may have led to some bias in the results. Furthermore, in all these studies, Poria cocos was one component of a multi-herb formula, making it impossible to attribute effects to Fu Ling alone.
Further investigations are required to determine optimal dosages, toxicity profiles, and clinical efficacy. Rigorous quality control, standardisation, and well-designed clinical trials are essential to validate its safety.
Evidence quality: Preclinical rodent models; one small human RCT using a combination product.
In animal studies, Poria cocos extract can improve sleep quality and structure by promoting inhibitory neurotransmission via GABAA receptors. Pentobarbital-induced sleep tests were conducted in normal ICR mice. Sleep latency and duration were checked with the righting reflex. To simulate a state of awakening as well as a normal sleep state, caffeine was administered orally. After oral gavage of the extract, sleep latency was decreased and total sleep duration was increased in normal and caffeine-induced sleep disturbance states.
In a human clinical study, in a 4-week, randomised, double-blind, controlled trial, 70 subjects with sleep disorders were randomly assigned to receive either a placebo or a Poria cocos, Ziziphus spinosa, and GABA (PZG) supplement (10 mL per day). Total sleep duration was detected by wrist actigraphy, and sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI). Skin conditions were also evaluated. After 4 weeks, total sleep duration significantly increased by 12.96% (p = .006) and the PSQI score notably decreased by 59.94% (p = .000) compared to baseline. This trial used a multi-ingredient product (PZG) rather than Fu Ling alone; therefore, the contribution of Poria cocos per se to the outcomes cannot be isolated.
P. cocos has long been used in traditional medicine for its tranquilising ("calming the spirit") properties. Recent pharmacological investigations indicate that its bioactive constituents exert multi-target regulatory effects on the central nervous system (CNS), demonstrating therapeutic potential for insomnia and anxiety.
Evidence quality: Predominantly in vitro and animal models; human prebiotic data from a single in vitro fermentation study.
Researchers have found that P. cocos and its extracts can regulate gastrointestinal motility, thereby enhancing digestive function and fluid metabolism in rats with spleen deficiency. In a study focused on antibiotic-associated diarrhoea, Poria cocos polysaccharides (PCP) have been validated for several biological activities, including antitumour, anti-inflammatory, antioxidant, immunomodulatory, hepatoprotective, and modulation of gut microbiota. An in vitro fecal fermentation model confirmed that P. cocos polysaccharides were readily utilised by the gut microbiota, as evidenced by a significant decrease in pH and an increase in SCFA concentrations. Notably, the relative abundance of beneficial bacteria (e.g., Lactobacillus and Bifidobacterium) increased, whereas that of potentially pathogenic taxa decreased. Furthermore, P. cocos polysaccharides enhanced the production of key microbial metabolites.
Evidence quality: Preclinical animal studies; no controlled human trials identified specifically for renal protection.
It demonstrates a wide range of pharmacological activities, including renal protection, improving digestive system function, enhancing sleep quality, immune regulation, antioxidant effects, anticancer properties, and the modulation of glucose-lipid metabolism. The specific triterpenoid poricoic acid A has shown activity in rodent models of kidney fibrosis, acting via AMPK pathway activation and gut microbiota rebalancing, as described in Section 4.7. These remain preclinical findings.
Evidence quality: In vitro and animal studies; no high-quality human RCTs identified for Fu Ling monotherapy.
Poria cocos is a medicinal fungus used for millennia in traditional Chinese medicine as a functional food and for the treatment of diabetes and other diseases. It and its active compounds can effectively control blood glucose and diabetic ulcers in animals and humans with diabetes. However, many of these findings come from in vitro or animal settings. The anti-diabetic mechanism of P. cocos and its triterpenes are likely due to their abilities to sensitise insulin-mediated glucose uptake.
Evidence quality: In vitro and animal experimental models; one limited human topical study.
Various studies of this fungus have demonstrated its marked anti-inflammatory activity in different experimental models of acute and chronic inflammation. In human volunteers with induced contact dermatitis, poria incorporated into an amphiphilic emollient cream was effective in the induction phase of inflammation, but not in well-established inflammation. This constitutes the only identified human-subject anti-inflammatory evidence and was a very limited study.
Evidence quality: Primarily preclinical animal and in vitro studies.
Pharmacological studies have confirmed that Poria cocos has diuretic, liver-protective, anti-inflammatory, antitumour, antioxidant, and antidiabetic effects. Interest in its hepatoprotective effects has grown in the context of metabolic dysfunction-associated steatotic liver disease (MASLD). A particular focus in recent reviews has been given to its antitumour effects, immunomodulatory activity, anti-obesity properties, mitigation of metabolic dysfunction-associated steatotic liver disease, and enhancement of intestinal barrier function.
It is widely used as a constituent of many preparations in Asian medicine, but the number of research papers on its clinical properties is insufficient for establishing its efficacy and safety from a scientific point of view. Most clinical evidence is based on combination preparations containing poria. Clinical studies in which P. cocos is only one of several chemical or plant derivatives included in preparations, which is common in traditional Chinese medicine, cannot be evaluated for the efficacy of poria alone. The majority of published mechanistic data derives from cell culture and rodent experiments. Robust, independent, placebo-controlled human clinical trials using Fu Ling as a single intervention across any indication remain limited.
Based on the totality of traditional texts and current pharmacological research, the following body systems and health domains are associated with Fu Ling:
Poria cocos is usually safe to use at pharmacopoeial doses (10–15 g), showing no toxicity to organs or mutagenicity. These pharmacopoeial doses refer to crude sclerotium used in decoctions or water-based preparations. In the clinical human sleep trial described above, the supplement was administered as 10 mL per day of a liquid formulation containing Poria cocos, Ziziphus spinosa, and GABA over 4 weeks. Poria cocos has low toxicity in mice, and there was no problem with oral administration of 6–18 g per day.
In pharmacological research, extracts and isolated compounds are used at much smaller doses corresponding to isolated or purified fractions — for example, poricoic acid A was tested at 20 mg/kg in mouse models of renal fibrosis. Standardised triterpenoid fractions are available commercially but dosage ranges for isolated triterpenoid extracts in clinical settings have not been established by large-scale human studies. The Chinese Pharmacopoeia specifies the general range for crude drug decoctions as 9–15 g per day.
The Shennong's Classic of Materia Medica classifies it as a superior herb, and clinically, Poria cocos is also considered to have high safety. Poria cocos is usually safe to use at pharmacopoeial doses (10–15 g), showing no toxicity to organs or mutagenicity. Poria cocos has also been confirmed to have no genetic toxicity.
In formal toxicology testing, in an acute toxicity test, rats were given a compound fuling decoction at a concentration of 720 g/kg, which was 100 times the patient's daily administration dosage, and all rats had no significant poisoning reaction. In long-term toxicity tests, there was no significant difference between the high-dose, middle-dose, low-dose groups and the control group. Thus, Poria cocos has no cumulative toxicity and is considered safe for clinical application.
Although there have been reports that Poria cocos can cause allergic reactions, this phenomenon is not common and may only be caused by individual differences.
The Chinese Pharmacopoeia lists poria as contraindicated in polyuria, spermatorrhoea, and urogenital prolapse. These contraindications have not been clinically validated in the modern evidence-based sense. Information regarding safety and efficacy in pregnancy and lactation is lacking.
No drug interactions are well documented, and reports of adverse events are lacking. With respect to metabolic drug interactions, a study investigating a Poria cocos and Morus alba extract mixture found no significant inhibitory effects on major liver enzymes involved in drug metabolism — specifically cytochrome P450 (CYP) and UGT enzymes — suggesting a low likelihood of metabolic herb–drug interactions. However, more targeted studies are needed to confirm safety across a broader range of drug classes.
There are still challenges in the dynamic balance between resource development and environmental protection, clarification of active ingredients, deepening of pharmacological mechanisms, and quality standardisation, especially in the qualitative and quantitative analysis of active ingredients (polysaccharides and triterpenoids) in Poria cocos, the risk of sulphur fumigation, and heavy metal pollution. Sulphur fumigation — a post-harvest preservation technique historically applied to reduce mould — has been identified as a concern in some Chinese-sourced material, as it may alter the polysaccharide profile and introduce sulphur dioxide residues. Purchasers of raw material and extracts should request verified, non-sulphur-fumigated material with heavy-metal testing certificates.
Health conditions that Fu ling may help support.
Both polysaccharides and triterpenoids of Poria cocos demonstrate antioxidant activity in preclinical models, elevating superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and reducing malondialdehyde (MDA). These effects are documented across hepatic, renal, and neurological injury models. In vitro antioxidant assays also confirm free radical scavenging.
Preclinical studies show Poria cocos water-soluble polysaccharides modulate anxiety-like behavior via the gut-brain axis, increasing serotonin, dopamine, and GABA levels. Pachymic acid, a key triterpene, interacts with GABA-A receptors and promotes serotonin release. Traditional TCM use for 'calming the Shen' aligns with these findings. Human clinical evidence remains limited.
Poria cocos bark extracts induced regulatory T cells (Tregs) and showed therapeutic effects in murine atopic dermatitis and food allergy models. Triterpenoid compounds from P. cocos have been used in formulas for rheumatoid arthritis and systemic lupus erythematosus. Immunomodulatory mechanisms involve Th1/Th2 balance modulation and NF-κB inhibition.
A 2022 PLOS ONE systematic review of 73 RCTs (6,489 participants) found that Fuling herbal formulae added to hypoglycaemic agents significantly reduced fasting blood glucose, 2-hour postprandial glucose, and HbA1c in type 2 diabetes. Triterpenes from P. cocos also showed anti-hyperglycaemic effects in animal models via PPAR-γ activation. Evidence is rated low-to-moderate due to risk of bias.
Poria cocos triterpenoids reduce total cholesterol and LDL while increasing HDL in dyslipidemic animal models. Polysaccharides promote reverse cholesterol transport and reduce hepatic lipid deposition. In a nephrotic syndrome rat model, P. cocos extract significantly reduced plasma total cholesterol and LDL-cholesterol.
Multiple preclinical studies demonstrate that Poria cocos ethanol extract and triterpenes suppress NF-κB signaling, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and mediators (NO, PGE2) in macrophage models. A PubMed review (2011) confirmed marked anti-inflammatory activity across multiple experimental models. Triterpenes inhibit phospholipase A2, a key enzyme in the arachidonic acid inflammatory cascade.
Multiple preclinical studies show Poria cocos polysaccharides and essential oils protect against Alzheimer's-model cognitive decline via AChE inhibition, hippocampal neuroprotection, reduction of oxidative stress, and MAPK/NF-κB pathway suppression. Pachymic acid is noted for maintaining cognitive homeostasis. Traditional TCM uses Fu Ling for amnesia, dementia, and longevity.
Preclinical rodent studies show P. cocos water extract exerts antidepressant-like effects in unpredictable chronic mild stress (UCMS) and forced swimming test (FST) models, increasing sucrose preference and reducing immobility. Mechanisms involve elevation of dopamine and serotonin in the frontal cortex and downregulation of neuroinflammation. No human clinical trials exist for depression as a primary endpoint.
A human skin study (PubMed 17026651) tested topical Poria cocos in three concentrations in a 4-day repetitive SLS-irritation model for irritant contact dermatitis (ICD), finding statistically significant anti-inflammatory activity by chromametry and transepidermal water loss. Triterpenoids also inhibited induced dermatitis in animal models via PLA2 inhibition.
Poria cocos polysaccharides have been studied for antibiotic-associated diarrhea (AAD) in preclinical models, showing restoration of gut microbiota homeostasis, increased tight junction protein ZO-1 expression, and improved intestinal mucosal barrier integrity. The Chinese Pharmacopoeia lists loose stools and diarrhea among Fu Ling's primary indications.
Multiple in vitro fecal fermentation studies demonstrate that Poria cocos polysaccharides act as prebiotics, significantly increasing Lactobacillus and Bifidobacterium while decreasing pathogenic taxa. SCFA production increases and gut microbiota diversity improves. These effects have been demonstrated using human fecal microbiota.
A clinical study (PMC10574255) in 21 adults with insomnia found that 800 mg nightly of Poria cocos ethanol extract significantly increased total sleep duration (327 to 357 min, p=0.014) and decreased sleep arousal, assessed by polysomnography. A 4-week RCT (n=70) with a P. cocos-containing combination supplement showed a 12.96% increase in total sleep duration and 59.94% improvement in PSQI scores.
Poria cocos exerts renal-protective effects via its diuretic action, anti-inflammatory properties, and antioxidant activity in preclinical kidney injury models. Carboxymethylated polysaccharides reduced TNF-α, IL-6, and IL-1β in septic acute kidney injury rats. Triterpenoids from the surface layer have demonstrated protective effects in chronic kidney disease models.
Poria cocos polysaccharides have demonstrated intestinal barrier-strengthening effects in preclinical models, upregulating tight junction protein ZO-1 in antibiotic-treated mice and preventing alcohol-induced gut leakiness. These effects are linked to reduction of intestinal inflammation and regulation of gut microbiota.
Poria cocos polysaccharides have demonstrated hepatoprotective effects in multiple preclinical models, reducing ALT, AST, and inflammatory markers in alcohol-induced and LPS/D-galactosamine-induced liver injury. P. cocos triterpenoids also promote reverse cholesterol transport and reduce liver lipid deposition. These effects are mediated via PI3K/AKT/NF-κB and antioxidant pathways.
Poria cocos polysaccharides (PCP) and essential oils have shown neuroprotective effects in Alzheimer's disease rat models, improving performance in Y-maze, Morris water maze, and novel object recognition tests. Mechanisms include acetylcholinesterase inhibition, reduction of hippocampal neuronal apoptosis, and suppression of MAPK/NF-κB signaling.
Poria cocos interacts with GABAergic, serotonergic, and dopaminergic systems in preclinical models, supporting sedative, anxiolytic, antidepressant, and neuroprotective functions. Polysaccharides protect hippocampal neurons in Alzheimer's models, and the herb appears in the Chinese Pharmacopoeia for neurological indications.
The Nutrients 2023 clinical study (n=21) using polysomnography demonstrated that 800 mg nightly Poria cocos ethanol extract significantly reduced sleep arousal, a direct measure of sleep maintenance. Animal studies also show reduced wake frequency during the sleep period following P. cocos administration.
Animal models demonstrate that P. cocos extracts reduce sleep latency and counteract caffeine-induced wakefulness, consistent with facilitation of sleep onset. The GABAergic mechanism of pachymic acid (BZD binding site activation) provides a plausible biological pathway for sleep onset facilitation.
Clinical human evidence supports Poria cocos improving overall sleep quality. An 800 mg/night clinical trial (n=21, polysomnography) showed significant increases in total sleep duration and reduced arousal. A separate 4-week RCT (n=70) reported a 59.94% improvement in PSQI scores. A meta-analysis of 13 RCTs (922 patients) also found sleep quality improvement in P. cocos-based formulas.
Preclinical studies in chronic unpredictable mild stress (UCMS) rat models demonstrate that P. cocos water extract and polysaccharides reduce stress-related behavioral deficits by downregulating neuroinflammation and normalizing monoamine levels. GABAergic modulation by pachymic acid provides a mechanistic basis for stress resilience.
Poria cocos triterpenoids and polysaccharides reduce serum triglycerides in preclinical dyslipidemia models. Triterpenoids reduce TG, LDL, and total cholesterol while increasing HDL in mice. Poria cocos oligosaccharides inhibit lipid accumulation in HFD-induced dyslipidemia, and P. cocos water extract reduced TG in a nephrotic syndrome rat model.
Poria cocos is one of the most extensively documented TCM diuretics, with the Chinese Pharmacopoeia listing edema and oliguria as primary indications. Animal studies confirm ethanol extracts of the surface layer produce marked diuresis, and the mechanism involves the AVP-V2R-AQP2 water channel axis. Clinical human data are limited.
Fu Ling is listed in the Chinese Pharmacopoeia for 'Spleen deficiency' with symptoms including abdominal pressure, bloating, loose stools, and diarrhea. Classical TCM formulas like Si Jun Zi Tang and Wu Ling San incorporate Fu Ling to address abdominal complaints linked to fluid accumulation and digestive weakness.
In TCM, Fu Ling is classified as a 'spirit-calming' (An Shen) herb, used for over 2,500 years to promote mental equilibrium and ease restlessness. The Chinese Pharmacopoeia lists it for restlessness and palpitations. Preclinical evidence supports GABAergic and serotonergic mechanisms underlying this property.
Fu Ling is classified in TCM as a Qi tonic and has been used for centuries for fatigue, weakness, and recovery from debilitating illness. It is listed among historical uses for 'recovery from long illness' and physical weariness. The Chinese Pharmacopoeia Shennong Bencao Jing classifies it as a superior herb for promoting vitality.
Classical TCM texts and pharmacological reviews document Fu Ling as a treatment for 'chronic gastritis, acute gastroenteric catarrh, and gastric atony.' The pachymic acid constituent has been noted for established effectiveness in chronic gastritis. TCM formulas incorporating Fu Ling are used for spleen-stomach disharmony underlying gastritis patterns.
Fu Ling is used in TCM for patterns corresponding to IBS symptoms — loose stools, diarrhea, abdominal bloating, and digestive weakness due to Spleen deficiency. Classical formulas like Si Jun Zi Tang and Shen Ling Bai Zhu San (specifically for Spleen deficiency with diarrhea) include Fu Ling as a core ingredient.
The Chinese Pharmacopoeia lists Fu Ling for 'phlegm' and 'productive cough,' and classical TCM texts describe it as resolving 'dampness and phlegm' accumulation. It is used in formulas such as Er Chen Tang for phlegm-related conditions. Scientific evidence for this specific indication is limited to its traditional context.
The inner layer of Poria cocos (Fu Ling) is traditionally used for nausea, emesis, and gastric atony in TCM and Japanese Kampo medicine. Classical indications recorded in the Chinese Pharmacopoeia and historical texts document its use for these gastrointestinal symptoms. Scientific evidence for this specific endpoint is absent.
Fu Ling has been used for over 2,500 years in TCM for urinary retention, oliguria, and urinary infections, documented in the Chinese Pharmacopoeia for 'edema and oliguria.' Classical formulas such as Wu Ling San address fluid retention and urinary dysfunction. Diuretic effects have been confirmed in animal studies but not human clinical trials.
The Chinese Pharmacopoeia explicitly lists dizziness (vertigo) among Fu Ling's primary indications, particularly dizziness arising from fluid accumulation and phlegm obstruction. Classical TCM formulas like Wu Ling San address fluid-related dizziness. No modern clinical trials support this indication.
Body systems that Fu ling may help support.
Go back